Literature DB >> 582985

[Time course of oxipurinol levels in plasma following single dose and chronic administration of allopurinol in different pharmaceutical preparations (author's transl)].

I Walter-Sack, W Gröbner, N Zöllner.   

Abstract

Oxipurinol plasma levels and plasma elimination half-life were investigated in five healthy volunteers after oral administration of 300 mg allopurinol in customary (A 300) and in slow-release preparation (A ret) in a double blind cross-over study. After a single oral dose of 300 mg allopurinol in customary preparation maximum oxipurinol plasma levels were 5.24 microgram/ml. After allopurinol in slow-release preparation maximum oxipurinol levels were 2.22 microgram/ml. 24-h oxipurinol plasma levels were 3.78 microgram/ml after A 300 and 2.08 microgram/ml after A ret, respectively. Chronic oral administration of a daily dose of 300 mg allopurinol resulted in accumulation of oxipurinol until day 8. 24-h steady-state levels of oxipurinol were found to be 9.98 microgram/ml after A 300 and 7.14 microgram/ml after A ret. All oxipurinol plasma levels on A 300 exceeded those on A ret. The time course of oxipurinol plasma levels after a single oral dose of allopurinol suggests that oxipurinol elimination from plasma follows an exponential function (first-order elimination). Plasma elimination half-life of oxipurinol was 42.65 h after administration of A 300 and 49.91 h after administration of A ret. The difference between the elimination half-lives is statistically not significant.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 582985

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  8 in total

Review 1.  The influence of nutrition on the systemic availability of drugs. Part II: Drug metabolism and renal excretion.

Authors:  I Walter-Sack
Journal:  Klin Wochenschr       Date:  1987-11-02

2.  Alteration of oral carbohydrate tolerance during administration of a fiber-free formula diet.

Authors:  I Walter-Sack; G Wolfram; N Zöllner
Journal:  Klin Wochenschr       Date:  1987-02-02

3.  Bioequivalence of allopurinol preparations: to be assessed by the parent drug or the active metabolite?

Authors:  I Walter-Sack; J X de Vries; C Kreiner; A Ittensohn; G Stenzhorn; A Voss; E Weber
Journal:  Clin Investig       Date:  1993-03

Review 4.  Clinical pharmacokinetics of allopurinol.

Authors:  G A Murrell; W G Rapeport
Journal:  Clin Pharmacokinet       Date:  1986 Sep-Oct       Impact factor: 6.447

5.  Allopurinol and oxypurinol in human breast milk.

Authors:  I Kamilli; U Gresser
Journal:  Clin Investig       Date:  1993-02

6.  Kinetics of allopurinol after single intravenous and oral doses. Noninteraction with benzbromarone and hydrochlorothiazide.

Authors:  B Breithaupt; M Tittel
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

7.  Interaction of allopurinol and hydrochlorothiazide during prolonged oral administration of both drugs in normal subjects. I. Uric acid kinetics.

Authors:  W Löffler; R Landthaler; J X de Vries; I Walter-Sack; A Ittensohn; A Voss; N Zöllner
Journal:  Clin Investig       Date:  1994-12

8.  The effect of benzbromarone on allopurinol/oxypurinol kinetics in patients with gout.

Authors:  F O Müller; R Schall; G Groenewoud; H K Hundt; J C van der Merwe; M van Dyk
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.